Blueprint Medicines Corp’s filing revealed that its Officer Christina Rossi acquired Company’s shares for reported $0.81 million on Mar 24 ’25. In the deal valued at $89.20 per share,9,096 shares were bought.
Then, Albers Jeffrey W. sold 5,766 shares, generating $512,021 in total proceeds. Upon selling the shares at $88.80, the Director now owns 146,630 shares.
Before that, Albers Jeffrey W. sold 7,500 shares. Blueprint Medicines Corp shares valued at $658,500 were divested by the Director at a price of $87.80 per share. As a result of the transaction, Albers Jeffrey W. now holds 152,396 shares, worth roughly $14.52 million.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Jefferies began covering BPMC with “Buy” recommendation on March 17, 2025. Scotiabank started covering the stock on March 07, 2025. It rated BPMC as “a Sector outperform”.
Price Performance Review of BPMC
On Monday, Blueprint Medicines Corp [NASDAQ:BPMC] saw its stock jump 7.38% to $95.27. Over the last five days, the stock has gained 3.40%. Blueprint Medicines Corp shares have risen nearly 9.23% since the year began. Nevertheless, the stocks have risen 7.94% over the past one year. While a 52-week high of $121.90 was reached on 01/27/25, a 52-week low of $80.68 was recorded on 03/10/25. SMA at 50 days reached $99.04, while 200 days put it at $97.08.
Levels Of Support And Resistance For BPMC Stock
The 24-hour chart illustrates a support level at 90.97, which if violated will result in even more drops to 86.68. On the upside, there is a resistance level at 97.79. A further resistance level may holdings at 100.32. The Relative Strength Index (RSI) on the 14-day chart is 55.15, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.20, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 6.56%. Stochastics %K at 60.62% indicates the stock is a holding.
How much short interest is there in Blueprint Medicines Corp?
A steep rise in short interest was recorded in Blueprint Medicines Corp stocks on 2025-02-28, growing by 0.5 million shares to a total of 4.71 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 4.21 million shares. There was a rise of 10.52%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on November 14, 2024 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $126 price target.
